| Trial | Name |
| 0C-04-3 | Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients with Hematologic Malignancies. |
| 0C-05-5 | A Phase I Trial of PXD101 in Combination with 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies. |
| 0C-05-8 | A Phase I Study of IV Fenretinide in Patients with Malignant Solid Tumors. |
| 0C-07-1 | A Pharmacokinetic Study of BMS-582664 in Subjects with Advanced Solid Tumor Malignancies and Normal Hepatic Function or Hepatocellular Carcinoma with Impaired Hepatic Function. |
| 0C-07-3 | Phase I Trial of Abraxane Administered on a Weekly and Three Weekly Schedule in Combination with Vandetanib. |
| 0C-07-5 | A Phase I Dose Escalation Study of MK-8033 in Patients with Advanced Solid Tumors. |
| 0C-07-9 | A Phase I and Pharmacokinetic Single Agent Study of Pazopanib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction. |
| 0C-08-4 | A Phase I Study of ABT-888 in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas. |
| 0C-09-3 | A Phase I, Multi-Arm, Dose Escalation Study of Brivanib Alaninate Combined with Several Chemotherapy Regimens in Subjects with Advanced or Metastatic Solid Tumors. |
| 0C-99-1 | Phase I Trial of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine. |
| 0I-05-2 | Open-Label Pharmacokinetic Trial of Aldesleukin (rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects with Metastatic Renal Cell Carcinoma or Metastatic Melanoma with Immunologic Correlative Studies. |
| 0S-00-15 | Molecular Determinants of Response and Survival to Fluoropyrimidines in Patients with GI Cancer. |
| 0S-00-16 | Molecular Determinants of Response and Survival to Platinum Compounds (Oxaliplatin and Cisplatin) in Patients with Cancer. |
| 0S-01-18 | Tumor Tissue Collection for Molecular Determinants in Patients with Cancer Treated with CPT-11-Based Chemotherapy. |
| 0S-03-2 | Comprehensive Tissue Repository: A Study of the Biology, Pathogenesis, Etiology, and Genetics of B-Cell and T-Cell Lymphoproliferative Disorders. |
| 0S-04-5 | Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients with Cancer. |
| 0S-04-7 | USC Tumor and Tissue Bank. |
| 0S-08-12 | A Phase II, Multi-Center, Two-Tier Study of IMC-A12 in Combination with Depot Octreotide in Patients with Metastatic, Well- or Moderately-Differentiated Carcinoid or Islet Cell Carcinoma. |
| 0S-08-6 | Collection of Peripheral Blood for Testing Feasibility of Dendritic Cell Culture and Transfection in Patients with Hematologic Disorders. |
| 0S-08-8 | Assessment of the Clinical Value of Supersonic Shear Wave Elastography in the Ultrasonic Evaluation of Breast Lesions. |
| 0S-08-9 | Short-Term Starvation Prior to Standard Chemotherapy with Gemcitabine and Cisplatin: Feasibility and Impact on Toxicity. |
| 0S-09-2 | A Phase II/III, Open Label, Non-Randomized, Multi-Center Study of Positron Emission Tomography (PET) Imaging with [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation. |
| 0S-09-3 | Prognostic Significance and Longitudinal Assessment of Patient-Reported Quality of Life and Symptoms in High-Risk Myelodysplastic Syndromes. A Large-Scale International, Observational Study. |
| 0S-09-4 | A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients with Elevated Tissue Factor Bearing Microparticles. |
| 0S-99-10 | Blood Collection in Patients with GI Cancer. |
| 13NHL-06-3 | A Phase I/IIa Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies. |
| 13NHL-07-3 | Rituximab Plus CHOP Given Every 15 days with Sargramostim in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. |
| 13NHL-09-2 | Phase I Study of GX15-070 (NSC #729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma. |
| 13NHL-09-4 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) versus Matching Placebo after Patients have Achieved Complete Response with First-Line Rituximab Chemotherapy. |
| 16M-08-1 | A Phase I/II, Multi-Center, Open-Label, Dose-Escalation Study of Elotuzumab (Humanized anti-CS1 Monoclonal IgG1 antibody, formerly HuLuc63) and Bortezomib in Subjects with Multiple Myeloma Following One to Three Prior Therapies. |
| 18M-07-1 | Phase II Study of AZD2171 (NSC#732208) in Patients with Malignant Mesothelioma. |
| 1B-04-4 | An International Randomized Controlled Trial to Compare Targeted Intra-Operative Radiotherapy with Conventional Post-Operative Radiotherapy after Conservative Breast Surgery for Women with Early Stage Breast Cancer. |
| 1B-06-10 | EphB4 Expression in Human Breast Cancer. |
| 1B-06-9 | Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast (TARGIT-DCIS Trial): Use of Mammography and Breast MRI to Identify Candidates for IORT. |
| 1B-07-3 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer. |
| 1B-08-1 | Pilot Study of Green Tea Supplement in Women with Ductal Carcinoma in Situ.
|
| 1B-08-2 | A Multi-Center Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab. |
| 1B-08-6 | MarginProbe, A Device for Intra-Operative Assessment of Margin Status in Breast Conservation Surgery (Margin ProbeTM Pivotal Study). |
| 1B-09-1 | A Phase II, Multi-Center, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer. |
| 1B-09-4 | A Multi-Center, Open-Label, Phase II Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic Breast Cancer Whose Disease has Failed Prior Taxane-Based Treatment. |
| 1B-09-7 | A Phase I/II, Open-Label Study of Neratinib (HKI-272) in Combination with Capecitabine in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or Locally Advanced Breast Cancer. |
| 1B-09-8 | A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Post-Menopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are Refractory to Letrozole or Anastrozole. |
| 2N-06-7 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Single-Agent Tarceva (Erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-Small Cell Lung Carcinoma who have EGFR-Positive Tumors. |
| 2N-06-8 | A Multi-Center, Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Cancer Vaccine Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Non-Small Cell Lung Cancer (NSCLC) Subjects with Unresectable Stage III Disease. |
| 2N-08-1 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Study of the Efficacy and Safety of Apricoxib in Combination with Erlotinib in Non-Small Cell Lung Cancer Patients. |
| 2N-08-6 | Development of DNA Methylation Markers for Early Detection of Lung Cancer. |
| 2N-09-3 | An Open-Label Phase II Multi-Center Study of the Safety and Activity (as Measured by FDG Pet Imaging Changes) of the Combination of Erlotinib and Pertuzumab in Patients with Relapsed Non-Small Cell Lung Cancer. |
| 2O-08-3 | A Phase IB/II Trial of AMG 479 or AMG 102 in Combination with Platinum-Based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer. |
| 3C-03-19 | Phase I/II Study of Celebrex and EPO906 in Patients with Metastatic Colorectal Cancer (CEPO906AUS10). |
| 3C-06-1 | A Pilot Study to Evaluate the Safety and Efficacy of Aprepitant in Combination with Dolasetron and Dexamethasone for the Prevention of Nausea and Vomiting Following Oxaliplatin-Containing Regimen Which Includes 5-FU. |
| 3C-07-5 | A Blinded, Randomized, Phase I/II Study of Brivanib Alaninate vs. Placebo in Combination with Erbitux and Irinotecan in K-Ras Wild Type Subjects with Metastatic Colorectal Cancer. |
| 3C-07-6 | A Phase I/II Trial of Pertuzumab in Combination with Cetuximab in Cetuximab-Refractory Metastatic Colorectal Cancer. |
| 3C-09-1 | A Phase II, Open-Label, Multi-Center Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients with Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status. |
| 3C-09-2 | A Multi-Center, Open-Label, Randomized, Phase II Study to Evaluate the Efficacy and Safety of NKTR-102 (PEG-Irinotecan) versus Irinotecan in Patients with Second-Line, Irinotecan-Naïve, KRAS-Mutant, Colorectal Cancer with Metastatic or Locally Advanced Disease. |
| 3G-03-4 | Phase II Study of Oxaliplatin, Xeloda, and Cetuximab as First-Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer. |
| 3G-03-5 | Phase II Study of Irinotecan and Docetaxel in Patients with Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma. |
| 3G-07-1 | A Randomized Phase II Study of Patients with Locally Advanced Gastric or Gastro-Esophageal Adenocarcinoma Treated with Induction Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Adjuvant Intraperitoneal Floxuridine Followed By Prolonged Administration of Capecitabine. |
| 3G-07-3 | Establishing Continuous Cell Lines and Xenografts from Adult Gastrointestinal Cancers and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies. |
| 3G-07-4 | Transcriptome-Based Microarrays as Predictors of Clinical Outcome in Patients with Metastatic and Locally Advanced Gastrointestinal Cancers. |
| 3G-09-1 | Phase IB Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination with Cisplatin and Capecitabine as First-Line Therapy in Patients with Inoperable Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas. |
| 3G-09-4 | A Phase IB Multiple Ascending Dose Study to Evaluate the Safety of Brivanib in Combination with 5-Fluorouracil/Leucovorin (5FU/LV) and Brivanib in Combination with 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) in Subjects with Advanced or Metastatic Gastrointestinal Malignancies. |
| 3L-03-1 | A Phase II Study of Intra-Arterial Chemotherapy with Cisplatin and Mitomycin-C in Patients with Hepatocellular Carcinoma. |
| 3L-06-3 | A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma. |
| 3L-08-1 | A Phase I, Open-Label, Multi-Center, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33, a Recombinant Humanized Antibody to Glypican-3 Administered Weekly in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC). |
| 3L-08-2 | A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation (STORM). |
| 3L-09-1 | GIDEON: Global Investigation of Therapeutic Decisions in Hepatocelluar Carcinoma and of its Treatment with Sorafenib |
| 3L-09-2 | A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma. |
| 3L-09-3 | A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC). |
| 3P-09-1 | Phase II Study of Gemcitabine and Intermittent Erlotinib in Advanced Pancreatic Cancer. |
| 3S-07-1 | An Exploratory, Phase II Trial to Determine the Association of Lapatinib-Induced Fluoropyrimidine Gene Changes with Efficacy Parameters of Lapatinib and Capecitabine in First-Line Gastric Cancer. |
| 4A-09-1 | A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma. |
| 4B-06-3 | A Randomized Phase II Study of Docetaxel +/- ZD6474 (Zactima) in Metastatic Transitional Cell Carcinoma. |
| 4K-05-1 | Phase I/II Trial of Bortezimib and Bevacizumab (“BB-mib-mab”) in Patients with Advanced or Recurrent Renal Cell Cancer (RCC) with Assessment of Tissue Correlates of Response. |
| 4K-08-5 | A Randomized, Open-Label, Multi-Center Phase II Study to Compare Bevacizumab plus RAD001 versus Interferon Alpha-2a plus Bevacizumab for the First-Line Treatment of Patients with Metastatic Clear Cell Carcinoma of the Kidney. |
| 4P-05-1 | FDG PET-CT in Metastatic Prostate Cancer. |
| 4P-06-3 | A Phase I/II Trial of Adjuvant 3-D Conformal Radiation Therapy, Hormonal Therapy, and Concurrent Docetaxel for High Risk Pathologic T2-T3N0M0 Prostate Cancer. |
| 4P-06-4 | Docetaxel (Taxotere) plus 6-Month Androgen Suppression and Radiation Therapy vs. 6-Month Androgen Suppression and Radiation Therapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial. |
| 4P-07-3 | A Phase II Trial of a Combination Herbal Therapy for Men with Biochemical Recurrence of Prostate Cancer After Initial Local Therapy. |
| 4P-08-4 | Diffusion-Weighted MRI for Staging in Localized Prostate Cancer: A Pilot Study. |
| 4P-09-2 | A Phase I/II. Open-Label, Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects. |
| 4P-09-6 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer. |
| 4P-09-8 | LHRH and LH Receptor Expression and Polymorphisms as Prognostic and Predictive Markers in Prostate Cancer. |
| 4T-03-1 | A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients with Refractory Germ Cell Carcinoma. |
| 5GYN-06-3 | A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft Tissue Sarcomas. |
| 5GYN-07-1 | A Phase III, Multi-Center, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma. |
| 5O-08-2 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-Like Growth Factor Type 1 Receptor (IGF-1R) to First-Line Chemotherapy in Patients with Optimally Debulked (<1 cm) Epithelial Ovarian Cancer. |
| 5O-08-3 | A Multi-Center Open Label Phase II Study of the Efficacy and Safety of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-Like Growth Factor Type 1 Receptor (IGF-1R) as Second-Line Therapy in Patients with Recurrent Platinum-Sensitive Ovarian Cancer. |
| 5O-09-1 | A Multi-Center, Open-Label, Phase II Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Unresectable Locally Advanced Platinum-Resistant Ovarian Cancer. |
| 6CNS-07-1 | Establishment of USC CNS and Spine Tumor Bank. |
| 7H-08-2 | Assessing the Role of Differentiated and Non-Differentiated Cell Types in the Development of Head and Neck Cancers. |
| 9L-03-1 | Treatment of Newly Diagnosed Adult Acute Lymphoblastic Leukemia with Intensified Post-Remission Therapy Containing PEG-Asparaginase. |
| 9L-06-1 | A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients 55 Years and Older with Acute Myelogenous Leukemia (AML) who have Relapsed or are Refractory after Receiving up to Two Prior Induction Regimens. |
| 9L-06-4 | A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation. |
| 9L-07-1 | A Phase II Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients with Philadelphia Chromosome-Negative ALL Who Failed Two Treatment Lines of Anti-Leukemia Chemotherapy. |
| 9L-07-13 | Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination with Cytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML). |
| 9L-08-3 | A Multi-Center, Open-Label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib. |
| ACRIN6678 | FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-Small Cell Lung Cancer. |
| AMC-048 | Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt’s and Atypical Burkitt’s Lymphoma. |
| AMC-053 | Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined with (R)ICE in Subjects with EBV and/or HHV-8 Positive Relapsed/ Refractory AIDS-Associated Non-Hodgkin’s Lymphoma. |
| AMC-059 | A Phase I/II Trial of PTC299 in Patients with HIV-Related Kaposi's Sarcoma. |
| ctsu/AcosogZ1031 | A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Post-Menopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer. |
| ctsu/Calgb80405 | A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum. |
| ctsu/Calgb90203 | A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer. |
| CTSU/CALGB90601 | A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma. |
| ctsu/E1505 | A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (=/>4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC). |
| CTSU/E2804 | The BeST Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma. |
| ctsu/E2805 | ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma. |
| CTSU/E3805 | CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer. |
| CTSU/E5103 | A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer. |
| ctsu/Ecog/PACCT-1 | Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial. |
| ctsu/Ibcsg2402 | A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Pre-Menopausal Women with Endocrine Responsive Breast Cancer. |
| ctsu/NsabpB42 | A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Post-Menopausal Women with Hormone Receptor Positive Breast Cancer. |
| GOG-0214 | Phase II Double-Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer (IND #79,610). |
| GOG-0240 | A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865, IND #7921) versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix. |
| GOG-0251 | A Phase II Trial of NCI–Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC #704865, IND #7921) For Recurrent Sex Cord-Stromal Tumors of the Ovary. |
| NSABP-R04 | A Clinical Trial Comparing Pre-Operative Radiation Therapy and Capecitabine With or Without Oxaliplatin With Pre-Operative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil With or Without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum. |
| RTOG-0517 | Randomized Phase III Trial to Evaluate RadioPharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer. |
| RTOG-0534 | A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy. |
| RTOG-0614 | A Randomized Phase III Double-Blind Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy. |
| RTOG-0619 | A Randomized Phase II Trial of Chemoradiotherapy versus Chemoradiotherapy and Vandetanib for High-Risk Post-Operative Advanced Squamous Cell Carcinoma of the Head and Neck. |
| SWOG-S0221 | Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer. |
| SWOG-S0230 | Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer. |
| SWOG-S0337 | A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer. |
| SWOG-S0421 | Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer. |
| SWOG-S0500 | A Randomized Phase III Trial to Test the Strategy of Changing Therapy versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment. |
| SWOG-S0518 | Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients. |
| SWOG-S0713 | A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab, and Radiation in Pre-Operative Therapy of Rectal Cancer. |
| SWOG-S0715 | Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane-Induced Neuropathy, Phase III. |
| SWOG-S0720 | Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC). |
| SWOG-S0727 | A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) vs. Gemcitabine + Erlotinib as First-Line Treatment in Patients with Metastatic Pancreatic Cancer. |
| SWOG-S0809 | A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC). |
| SWOG-S9910 | Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary. |
| SWOG-S9925 | Lung Cancer Specimen Repository Protocol, Ancillary. |
